LONDON--(BUSINESS WIRE)--The Dravet syndrome treatment market is set to grow by USD 396.15 million accelerating at a CAGR of over 9%, during the period spanning over 2020-2024. One of the key factors driving growth is the rising strategic alliances. Several pharmaceutical companies are working together to develop drugs for the treatment of Dravet syndrome. Increasing new product launches is a significant trend that will further stimulate market growth. Increasing product launches are making the market more competitive and increasing the availability of drugs for patients.
To learn more about the global trends impacting the future of market research, download a free sample now
Parent Market Analysis
Technavio categorizes the Dravet syndrome treatment market as a part of the pharmaceutical market within the overall healthcare industry. The parent, pharmaceuticals market covers products and companies engaged in R&D or production of generic drugs, non-generic drugs, and veterinary drugs.
Growth in the healthcare market will be driven by factors such as increasing life expectancy, improving access to better healthcare in emerging economies, rising prevalence of sedentary lifestyle, rising cases of chronic conditions, and rising number of partnerships between pharmaceutical companies.
Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts
Dravet Syndrome Treatment Market: Segmentation by Geography
The report segments the market by Geography: North America, Europe, Asia, and ROW. 44% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for Dravet syndrome treatment in North America.
Dravet Syndrome Treatment Market: Segmentation by Product
The SGDs segment was leading the market in 2019. This report provides an accurate prediction of the contribution of all the segments to the growth of the Dravet syndrome treatment market size.
Dravet Syndrome Treatment Market: Growth Drivers
The market is driven by the rising number of strategic alliances among vendors. Many vendors in the market are partnering with other vendors to develop effective drugs for the treatment of Dravet syndrome. For instance, in September 2018, Supernus Pharmaceuticals Inc. announced its plans to acquire Biscayne Neurotherapeutics (Biscayne), a privately-held company developing a novel treatment for epilepsy. Similarly, in August 2020, Takeda and Ovid completed the Phase II trials of the Dravet syndrome drug and are planning for the Phase III registrational trials. Such developments are expected to boost market growth during the forecast period.
Dravet Syndrome Treatment Market: Challenges to Overcome
Many patients who do not respond to medications are looking for alternative treatment methods to treat Dravet syndrome. Some of the alternative treatment options such as herbs, vitamins, biofeedback, acupuncture, VNS, and keto diet are gaining popularity, which is affecting the growth of market vendors.
Dravet Syndrome Treatment Market: Vendor landscape
This report provides information on revenue, organizational developments, and key go-to-market strategies of several leading Dravet syndrome treatment companies, including:
- AbbVie Inc.
- BIOCODEX SAS
- Epygenix Therapeutics Inc.
- GW Pharmaceuticals Plc
- H. Lundbeck AS
- Johnson & Johnson
- PTC Therapeutics Inc.
- Supernus Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- Zogenix Inc.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Technavio reports cover the following key research areas:
- Detailed Analysis of Market Eco System
- Market favorability index
- Market opportunity by segments
- Analysis of drivers of price sensitivity
- Key purchase criteria
- Customer purchase basket
- Impact of drivers and Challenges
- Factors of differentiation
- Landscape disruption
- Key industry risks
- Market position of vendors
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.